CXCL9 and neoplasm: Furthermore, inhibition of LINC00152 may increase the number of tumor-infiltrating CD8+ T cells and promote the expression of CXCL9, CXCL10, and C-X-C Motif chemokine receptor 3 (CXCR3) in xenograft tumors, thereby achieving the goal of tumor suppression.